晚期胃癌治疗中预测和预后生物标志物的演变。
Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.
机构信息
Merck & Co., Inc., 90 E. Scott Avenue, Rahway, NJ, 07065, USA.
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
出版信息
J Cancer Res Clin Oncol. 2022 Aug;148(8):2023-2043. doi: 10.1007/s00432-021-03902-1. Epub 2022 May 13.
Abstract
Despite new therapeutic options, advanced gastric cancer remains associated with a poor prognosis compared with other cancers. Recent gains in the treatment of gastric cancer were accompanied by the identification of novel biomarkers associated with various cellular pathways and corresponding diagnostic technologies. It is expected that the standardization of clinical workflow and technological refinements in biomarker assessment will support greater personalization and further improve treatment outcomes. In this article, we review the current state of prognostic and predictive biomarkers in gastric cancer.
摘要
尽管有新的治疗选择，但与其他癌症相比，晚期胃癌的预后仍然较差。胃癌治疗的最新进展伴随着与各种细胞通路相关的新型生物标志物的发现和相应的诊断技术。预计临床工作流程的标准化和生物标志物评估技术的改进将支持更大程度的个性化，并进一步改善治疗效果。本文综述了胃癌预后和预测生物标志物的现状。
相似文献
1
Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.晚期胃癌治疗中预测和预后生物标志物的演变。
J Cancer Res Clin Oncol. 2022 Aug;148(8):2023-2043. doi: 10.1007/s00432-021-03902-1. Epub 2022 May 13.
2
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.程序性死亡受体 1 配体（PD-L1）与胃癌预后：一项系统评价和荟萃分析。
PLoS One. 2017 Aug 10;12(8):e0182692. doi: 10.1371/journal.pone.0182692. eCollection 2017.
3
GNGT1 is a potential prognostic and immunologic biomarker in gastric cancer.GNGT1是胃癌中一种潜在的预后和免疫生物标志物。
Sci Rep. 2025 Jul 1;15(1):21149. doi: 10.1038/s41598-025-08297-4.
4
Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-Analysis.B7同源物1在胃癌中的临床病理意义及预后价值：一项系统评价和Meta分析
Medicine (Baltimore). 2015 Oct;94(43):e1911. doi: 10.1097/MD.0000000000001911.
5
B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy.B7-H3与CD47在胃癌中的共表达是预后不良的预测指标，也是未来双靶点免疫治疗的潜在靶点。
J Cancer Res Clin Oncol. 2023 Dec;149(18):16609-16621. doi: 10.1007/s00432-023-05408-4. Epub 2023 Sep 16.
6
Identification of HCAR1 as a ferroptosis-related biomarker of gastric cancer based on a novel ferroptosis-related prognostic model and in vitro experiments.基于一种新型铁死亡相关预后模型及体外实验鉴定HCAR1作为胃癌铁死亡相关生物标志物
Carcinogenesis. 2025 Apr 3;46(2). doi: 10.1093/carcin/bgaf030.
7
Remnant gastric cancer: a neglected group with high potential for immunotherapy.残胃癌：一个被忽视但免疫治疗潜力巨大的群体。
J Cancer Res Clin Oncol. 2020 Dec;146(12):3373-3383. doi: 10.1007/s00432-020-03322-7. Epub 2020 Jul 15.
8
Expression Patterns of Immune Checkpoint Molecules and Their Clinical Values in Gastric Neuroendocrine Neoplasms.免疫检查点分子在胃神经内分泌肿瘤中的表达模式及其临床价值
Clin Transl Gastroenterol. 2025 Apr 4;16(6):e00842. doi: 10.14309/ctg.0000000000000842. eCollection 2025 Jun 1.
9
Relationship between programmed cell death ligand 1 expression and the number of biopsy specimens in advanced gastric cancer.晚期胃癌中程序性细胞死亡配体1表达与活检标本数量的关系。
J Cancer Res Clin Oncol. 2025 Jul 8;151(7):206. doi: 10.1007/s00432-025-06255-1.
10
Molecular-targeted first-line therapy for advanced gastric cancer.晚期胃癌的分子靶向一线治疗
Cochrane Database Syst Rev. 2016 Jul 19;7(7):CD011461. doi: 10.1002/14651858.CD011461.pub2.
引用本文的文献
1
Development and validation of liquid-liquid phase separation-associated prognostic biomarkers in gastric cancer.胃癌中液-液相分离相关预后生物标志物的开发与验证
Discov Oncol. 2025 May 30;16(1):963. doi: 10.1007/s12672-025-02804-9.
2
Biomarkers used in the diagnosis and prognosis of gastric cancer in young patients: a scientometric analysis.用于年轻患者胃癌诊断和预后的生物标志物：一项科学计量学分析。
Front Med (Lausanne). 2025 Apr 9;12:1586742. doi: 10.3389/fmed.2025.1586742. eCollection 2025.
3
Immunotherapy for metastatic gastric cancer.转移性胃癌的免疫疗法。
World J Gastrointest Surg. 2024 Nov 27;16(11):3408-3412. doi: 10.4240/wjgs.v16.i11.3408.
4
Potential role of lncRNA LOXL1-AS1 in human cancer development: a narrative review.长链非编码RNA LOXL1-AS1在人类癌症发展中的潜在作用：一篇叙述性综述
Transl Cancer Res. 2024 Apr 30;13(4):1997-2011. doi: 10.21037/tcr-23-1450. Epub 2024 Apr 12.
5
Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma.佐贝妥昔单抗联合mFOLFOX6作为CLDN18.2阳性、HER2阴性晚期胃癌或胃食管腺癌一线治疗的成本效益分析
Front Pharmacol. 2023 Aug 31;14:1238009. doi: 10.3389/fphar.2023.1238009. eCollection 2023.
6
Apolipoprotein C1 promotes tumor progression in gastric cancer.载脂蛋白 C1 促进胃癌肿瘤进展。
Oncol Res. 2023 May 24;31(3):287-297. doi: 10.32604/or.2023.028124. eCollection 2023.
7
Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma.zolbetuximab 在日本 CLDN18.2+胃或胃食管结合部腺癌患者中的 1 期临床试验。
Cancer Sci. 2023 Apr;114(4):1606-1615. doi: 10.1111/cas.15684. Epub 2022 Dec 25.
8
Adenosine signaling: Optimal target for gastric cancer immunotherapy.腺苷信号：胃癌免疫治疗的最佳靶点。
Front Immunol. 2022 Sep 16;13:1027838. doi: 10.3389/fimmu.2022.1027838. eCollection 2022.
本文引用的文献
1
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.一线纳武利尤单抗联合化疗与单纯化疗治疗晚期胃癌、胃食管交界癌和食管腺癌（CheckMate 649）：一项随机、开放标签的3期试验。
Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.
2
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma.帕博利珠单抗对比紫杉醇用于随机、开放标签、III 期临床试验中胃食管腺癌患者的临床结局的分子决定因素。
Ann Oncol. 2021 Sep;32(9):1127-1136. doi: 10.1016/j.annonc.2021.05.803. Epub 2021 May 31.
3
Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?晚期胃癌中新型HER2靶向治疗：又一次范式转变？
Cancers (Basel). 2021 Apr 1;13(7):1664. doi: 10.3390/cancers13071664.
4
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.评估帕博利珠单抗治疗微卫星不稳定高或胃食管结合部癌患者的疗效：KEYNOTE-059、KEYNOTE-061 和 KEYNOTE-062 临床试验结果。
JAMA Oncol. 2021 Jun 1;7(6):895-902. doi: 10.1001/jamaoncol.2021.0275.
5
Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.卡瑞利珠单抗联合化疗后序贯卡瑞利珠单抗加阿帕替尼作为晚期胃或胃食管交界腺癌的一线治疗方案
Clin Cancer Res. 2021 Jun 1;27(11):3069-3078. doi: 10.1158/1078-0432.CCR-20-4691. Epub 2021 Mar 25.
6
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.高肿瘤突变负担未能预测所有癌症类型的免疫检查点阻断反应。
Ann Oncol. 2021 May;32(5):661-672. doi: 10.1016/j.annonc.2021.02.006. Epub 2021 Mar 15.
7
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.FAST：一项关于zolbetuximab（IMAB362）联合EOX 对比 EOX 一线治疗晚期 CLDN18.2 阳性胃和胃食管腺癌的随机 II 期研究。
Ann Oncol. 2021 May;32(5):609-619. doi: 10.1016/j.annonc.2021.02.005. Epub 2021 Feb 19.
8
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.《2021年临床癌症进展：美国临床肿瘤学会抗癌进展报告》
J Clin Oncol. 2021 Apr 1;39(10):1165-1184. doi: 10.1200/JCO.20.03420. Epub 2021 Feb 2.
9
Correlation between Claudin-18 expression and clinicopathological features and prognosis in patients with gastric cancer.Claudin-18表达与胃癌患者临床病理特征及预后的相关性
J Gastrointest Oncol. 2020 Dec;11(6):1253-1260. doi: 10.21037/jgo-20-463.
10
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10.帕博利珠单抗单药治疗 PD-L1 联合阳性评分≥10 的晚期胃/胃食管结合部癌的疗效。
Clin Cancer Res. 2021 Apr 1;27(7):1923-1931. doi: 10.1158/1078-0432.CCR-20-2980. Epub 2021 Jan 14.
Zotero 插件